Company Profile
Journey Medical Corporation Stock Price, News & Analysis
- Ticker:
- DERM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.53 USD (+2.03%)
Close
Last updated: August 6, 2026
166M USD
Market cap
Why the stock is moving
The latest monitored headline was “Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026”. DERM was little changed in the corresponding trading session, closing at $6.40 on Aug 5, 2026.
Company overview
Prescription Dermatology Company
Journey Medical develops, acquires, and commercializes FDA-approved prescription products for dermatologic conditions through a specialist sales organization.
Emrosi
Emrosi is the company’s newer treatment for inflammatory lesions of rosacea and is central to its current commercial expansion.
Established Portfolio
Journey also markets a broader group of branded dermatology products, allowing its sales infrastructure to support multiple prescriptions and disease categories.
Efficient Commercial Model
The company emphasizes targeted product acquisition and focused physician promotion rather than maintaining a broad internal drug-discovery platform.
Future catalysts
The main thing to watch at Journey Medical Corporation is its latest development priorities. The update that sharpened the story was FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea. That is the part of the story investors will probably keep circling back to.
Recent news
- 01
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Source: Journey Medical Corporation
- 02
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Source: Journey Medical Corporation
- 03
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Source: Journey Medical Corporation
- 04
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Source: Journey Medical Corporation
- 05
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Source: Journey Medical Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Journey Medical Corporation (DERM)?
Journey Medical Corporation (DERM) most recently closed at 6.53 USD, a +2.03% move versus the previous session.
What is the market cap of Journey Medical Corporation (DERM)?
Journey Medical Corporation currently has a market capitalization of 166M USD on BioPharmSignal.
What does Journey Medical Corporation do?
Prescription Dermatology Company Journey Medical develops, acquires, and commercializes FDA-approved prescription products for dermatologic conditions through a specialist sales organization. Emrosi Emrosi is the company’s newer treatment for inflammatory lesions of rosacea and is central to its current commercial expansion. Established Portfolio Journey...
On which exchange is DERM stock listed?
Journey Medical Corporation (DERM) is associated with NASDAQ, United States, Biopharma.
What is Prescription?
Prescription Dermatology Company Journey Medical develops, acquires, and commercializes FDA-approved prescription products for dermatologic conditions through a specialist sales organization.
Which conditions is Journey Medical Corporation targeting with Prescription?
Journey Medical Corporation is associated with dermatology based on its company overview and current catalyst commentary.
How does Journey Medical Corporation describe recent progress with Prescription?
The main thing to watch at Journey Medical Corporation is its latest development priorities. The update that sharpened the story was FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea. That is the part of the story investors will probably keep circling back to.
What is Dermatology?
Prescription Dermatology Company Journey Medical develops, acquires, and commercializes FDA-approved prescription products for dermatologic conditions through a specialist sales organization.